Disease activity improvements with optimal discriminatory ability between treatment arms: applicability in early and established rheumatoid arthritis clinical trials

BACKGROUND: The ACR20 has been validated as the best discriminator of efficacy in placebo-controlled trials, but not in head-to-head trials comparing effective therapies in patients with rheumatoid arthritis (RA). We assessed the most discriminatory ACR response and most discriminatory percent impro...

Descripción completa

Detalles Bibliográficos
Autores principales: Smolen, Josef, Fleischmann, Roy, Aletaha, Daniel, Li, Yihan, Zhou, Yijie, Sainsbury, Iain, Galindo, Ivan Lagunes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6842479/
https://www.ncbi.nlm.nih.gov/pubmed/31707982
http://dx.doi.org/10.1186/s13075-019-2005-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6842479/
https://www.ncbi.nlm.nih.gov/pubmed/31707982
http://dx.doi.org/10.1186/s13075-019-2005-9

Ejemplares similares